6.845 USD
-0.02 (-0.22%)
We assign a fundamental rating of 4 out of 10 to NVAX. NVAX was compared to 534 industry peers in the Biotechnology industry. NVAX has a medium profitability rating, but doesn't score so well on its financial health evaluation. NVAX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NVAX was profitable.
NVAX had a negative operating cash flow in the past year.
NVAX had negative earnings in each of the past 5 years.
NVAX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of NVAX (28.96%) is better than 98.13% of its industry peers.
With an excellent Return On Invested Capital value of 43.90%, NVAX belongs to the best of the industry, outperforming 99.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.96% | ||
| ROE | N/A | ||
| ROIC | 43.9% |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVAX has a better Profit Margin (32.10%) than 96.44% of its industry peers.
Looking at the Operating Margin, with a value of 39.15%, NVAX belongs to the top of the industry, outperforming 98.31% of the companies in the same industry.
The Gross Margin of NVAX (91.82%) is better than 92.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.15% | ||
| PM (TTM) | 32.1% | ||
| GM | 91.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NVAX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
NVAX has more shares outstanding than it did 1 year ago.
NVAX has more shares outstanding than it did 5 years ago.
NVAX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.32, we must say that NVAX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.32, NVAX is in line with its industry, outperforming 49.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.32 |
ROIC/WACC5.05
WACC8.69%
2.3 Liquidity
NVAX has a Current Ratio of 2.27. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
NVAX has a worse Current ratio (2.27) than 72.28% of its industry peers.
NVAX has a Quick Ratio of 2.24. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
NVAX's Quick ratio of 2.24 is on the low side compared to the rest of the industry. NVAX is outperformed by 70.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 165.04% over the past year.
Looking at the last year, NVAX shows a very strong growth in Revenue. The Revenue has grown by 20.27%.
Measured over the past years, NVAX shows a very strong growth in Revenue. The Revenue has been growing by 105.31% on average per year.
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
Revenue 1Y (TTM)20.27%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%
3.2 Future
The Earnings Per Share is expected to grow by 17.51% on average over the next years. This is quite good.
The Revenue is expected to decrease by -13.97% on average over the next years. This is quite bad
EPS Next Y241%
EPS Next 2Y46.07%
EPS Next 3Y26.3%
EPS Next 5Y17.51%
Revenue Next Year55.73%
Revenue Next 2Y-19.75%
Revenue Next 3Y-25.15%
Revenue Next 5Y-13.97%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
NVAX is valuated cheaply with a Price/Earnings ratio of 4.66.
Based on the Price/Earnings ratio, NVAX is valued cheaper than 99.25% of the companies in the same industry.
When comparing the Price/Earnings ratio of NVAX to the average of the S&P500 Index (26.41), we can say NVAX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 31.03, the valuation of NVAX can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NVAX indicates a rather cheap valuation: NVAX is cheaper than 91.39% of the companies listed in the same industry.
NVAX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 35.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.66 | ||
| Fwd PE | 31.03 |
4.2 Price Multiples
NVAX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NVAX is cheaper than 99.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.24 |
4.3 Compensation for Growth
NVAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NVAX's earnings are expected to grow with 26.30% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y46.07%
EPS Next 3Y26.3%
5. Dividend
5.1 Amount
No dividends for NVAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NVAX (12/5/2025, 9:45:09 AM)
6.845
-0.02 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.63%
Inst Owner Change1.54%
Ins Owners0.41%
Ins Owner Change6.08%
Market Cap1.11B
Revenue(TTM)1.06B
Net Income(TTM)341.74M
Analysts73.33
Price Target13.9 (103.07%)
Short Float %34.18%
Short Ratio11.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)412.33%
Min EPS beat(2)-3.3%
Max EPS beat(2)827.96%
EPS beat(4)2
Avg EPS beat(4)268.3%
Min EPS beat(4)-58.31%
Max EPS beat(4)827.96%
EPS beat(8)4
Avg EPS beat(8)103.35%
EPS beat(12)7
Avg EPS beat(12)71.73%
EPS beat(16)7
Avg EPS beat(16)-6.56%
Revenue beat(2)2
Avg Revenue beat(2)61.22%
Min Revenue beat(2)58.52%
Max Revenue beat(2)63.92%
Revenue beat(4)4
Avg Revenue beat(4)53.78%
Min Revenue beat(4)2.61%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)24.49%
Revenue beat(12)7
Avg Revenue beat(12)22.3%
Revenue beat(16)8
Avg Revenue beat(16)9.73%
PT rev (1m)2.55%
PT rev (3m)-6.49%
EPS NQ rev (1m)-11.36%
EPS NQ rev (3m)28.33%
EPS NY rev (1m)-10.59%
EPS NY rev (3m)1%
Revenue NQ rev (1m)-22.17%
Revenue NQ rev (3m)-28.39%
Revenue NY rev (1m)-1.09%
Revenue NY rev (3m)-1.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.66 | ||
| Fwd PE | 31.03 | ||
| P/S | 1.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 0.24 |
EPS(TTM)1.47
EY21.48%
EPS(NY)0.22
Fwd EY3.22%
FCF(TTM)-2.36
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS6.55
BVpS-0.96
TBVpS-1.66
PEG (NY)0.02
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.96% | ||
| ROE | N/A | ||
| ROCE | 55.58% | ||
| ROIC | 43.9% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 39.15% | ||
| PM (TTM) | 32.1% | ||
| GM | 91.82% | ||
| FCFM | N/A |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.54 | ||
| Cap/Depr | 15.47% | ||
| Cap/Sales | 0.51% | ||
| Interest Coverage | 19.68 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.24 | ||
| Altman-Z | -2.32 |
F-Score6
WACC8.69%
ROIC/WACC5.05
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
EPS Next Y241%
EPS Next 2Y46.07%
EPS Next 3Y26.3%
EPS Next 5Y17.51%
Revenue 1Y (TTM)20.27%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%
Revenue Next Year55.73%
Revenue Next 2Y-19.75%
Revenue Next 3Y-25.15%
Revenue Next 5Y-13.97%
EBIT growth 1Y243.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year310.32%
EBIT Next 3Y13.97%
EBIT Next 5YN/A
FCF growth 1Y46.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.24%
OCF growth 3YN/A
OCF growth 5YN/A
NOVAVAX INC / NVAX FAQ
Can you provide the ChartMill fundamental rating for NOVAVAX INC?
ChartMill assigns a fundamental rating of 4 / 10 to NVAX.
Can you provide the valuation status for NOVAVAX INC?
ChartMill assigns a valuation rating of 6 / 10 to NOVAVAX INC (NVAX). This can be considered as Fairly Valued.
How profitable is NOVAVAX INC (NVAX) stock?
NOVAVAX INC (NVAX) has a profitability rating of 4 / 10.
How financially healthy is NOVAVAX INC?
The financial health rating of NOVAVAX INC (NVAX) is 3 / 10.